Loading clinical trials...
Loading clinical trials...
Screening for Albuminuria at the First Line for Early Identification of Chronic Kidney Disease: a Pilot Study
Early detection of kidney disease
Early detection and appropriate treatment of kidney disease is important as this may prevent future cardiovascular complications and end-organ damage more effectively than intervention in more advanced stages of disease. There is a well-established relationship between albuminuria and renal- and cardiovascular disease. Elevated albuminuria has a relatively high prevalence in the general population (5-9%). The prevalence of albuminuria is even higher in high-risk patients with diabetes Mellitus, hypertension, obesity, cardiovascular disease and lipid disorders. Adequate treatment of albuminuria, preferable at early stages can prevent both cardiovascular and renal disease progression. However, scarce epidemiological data show that albuminuria measurements are only conducted in a minority of individuals and disease recognition is suboptimal, even in high-risk groups. The current study aims to evaluate if and how early identification of chronic kidney disease by targeted screening of albuminuria levels is feasible in primary care (pharmacies and general practitioners) to optimally discover and treat patients with elevated albuminuria.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
General Practitioners Research Institute
Groningen, Netherlands
Start Date
November 25, 2021
Primary Completion Date
December 31, 2023
Completion Date
July 30, 2024
Last Updated
August 9, 2024
141
ACTUAL participants
Albuminuria test
DIAGNOSTIC_TEST
HbA1c test
DIAGNOSTIC_TEST
Creatinine test
DIAGNOSTIC_TEST
Lead Sponsor
General Practitioners Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07358572